NCT02367053已完成1 期
A Randomized, Double-blinded Trial of Single Ascending Doses of ZP4207 Administered s.c. or i.m. to HV and a SD of ZP4207 Administered s.c. to Hypoglycemic T1D to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207 as Compared to an Active Comparator
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 111
- 试验地点
- 1
- 主要终点
- Safety and Tolerability: Number of participants with adverse events
研究概览
简要总结
The trial is a randomized, double-blind First in Human trial to evaluate the safety and tolerability of ZP4207 in healthy volunteers (HV) and in insulin-induced hypoglycemic T1D (type 1 diabetes) subjects as compared to native glucagon. The trial includes two parts.
Part 1 includes dose escalation of ZP4207 in cohorts of 8 subjects. In each cohort, subjects will be randomized 3:1 to receive either a single ascending dose of ZP4207 (6 subjects) or a single fixed dose (SD) of native glucagon (2 subjects). The doses will be administered s.c. in 4-5 cohorts and i.m. in 3 cohorts.
Part 2 includes two sequence groups of 10 hypoglycemic T1D subjects. The subjects will be treated with fixed single doses of ZP4207 and native glucagon s.c. in a sequential cross-over design in a randomized treatment order.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).
- •Male subjects which are healthy for part 1; for part 2 male subjects with T1D
- •Age between 18 and 50 years, both inclusive.
- •Body weight between 70 and 90 kg, both inclusive.
- •Subjects must be in good health according to age (medical history, physical examination, vital signs, ECG, lab assessments), as judged by the investigator
- •A subject who is surgically sterilized or must be willing to refrain from sexual intercourse during the trial and until one month after completion of the trial or if sexually active, using condom and partner practices contraception during the trial and until one month after completion of the trial.
- •For part 2, in addition:
- •Male subjects with T1D for at least one year, as defined by the American Diabetes Association.
- •Having been treated with insulin for T1D for at least 1 year.
- •Stable disease with HbA1c < 8.5 %.
- •Stable insulin treatment during participation in trial and 3 month prior to the screening visit.
排除标准
- •Known or suspected allergy to trial product(s) or related products.
- •Previous participation (randomization) in this trial.
- •Receipt of any investigational drug within 3 months prior to screening.
- •A history or presence of cancer, diabetes (part 1 only), or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, hematological, dermatological, venereal, neurological, psychiatric diseases or other major diseases.
- •Clinically significant illness within 4 weeks before screening, as judged by the investigator
- •Carrier of Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies.
- •Positive result of test for HIV antibodies.
- •Any clinically significant abnormal hematology,biochemistry or urinalysis screening tests, as judged by the Investigator.
- •Clinically significant abnormal ECG at screening as evaluated by Investigator.
- •Donation of blood or plasma in the past month, or in excess of 500 ml within 12 weeks prior to screening.
- •A significant history of alcoholism or drug/chemical abuse, or who has a positive result in the urine drug screen, or who consumes more than 28 units of alcohol per week (one unit of alcohol equals about 250 ml of beer, 1 glass of wine, or 20 ml of spirits).
- •Habitual smoking, i.e., daily smoking or more than 7 cigarettes/week within the last 3 months prior to screening. Subjects have to accept refraining from smoking while at the clinical site.
- •Subjects with mental incapacity or language barriers which preclude adequate understanding or cooperation, who are unwilling to participate in the trial, or who in the opinion of the Investigator should not participate in the trial.
- •Surgery or trauma with significant blood loss within the last 2 months prior to screening.
- •Any condition interfering with trial participation or evaluation or that may be hazardous to the subject.
- •For part 2, in addition
- •Severe hypoglycemic events within one year prior to screening, as judged by the investigator.
- •Significant changes in basal insulin within 3 weeks before screening, as judged by the investigator.
- •Clinically relevant diabetic complications (macrovascular disease with symptoms of coronary artery disease or peripheral vascular disease, microvascular disease with symptoms of neuropathy, gastroparesis, retinopathy, nephropathy, or poor blood glucose control with polyuria, polydipsia, or weight loss), as judged by the investigator.
研究组 & 干预措施
ZP4207
Experimental
single dose of ZP4207 in ascending doses (s.c. and i.m.)
干预措施: ZP4207 (Drug)
native glucagon
Active Comparator
single fixed dose of glucagon
干预措施: Glucagon (Drug)
结局指标
主要结局
Safety and Tolerability: Number of participants with adverse events
时间窗: 28 days
Safety and Tolerability: Changes or findings from baseline in clinical safety laboratory assessments
时间窗: 28 days
Safety and Tolerability: Changes or findings from baseline in physical examination
时间窗: 28 days
Safety and Tolerability: Changes or findings from baseline in vital signs
时间窗: 28 days
Safety and Tolerability: Changes or findings from baseline in ECG
时间窗: 28 days
Safety and Tolerability: Findings in local tolerability
时间窗: 28 days
次要结局
- Pharmacokinetics (PK): Area under the curve (AUC) from time-point 0 until 300min(5 hours)
- Pharmacokinetics: maximum observed concentration of ZP4207 (Cmax)(5 hours)
- Pharmacokinetics: time to maximum observed concentration of ZP4207 (tmax)(5 hours)
- Pharmacokinetics: terminal elimination rate constant estimated during the terminal phase of ZP4207 (λz)(5 hours)
- Pharmacokinetics: the terminal plasma elimination half-life of ZP4207 (t½),(5 hours)
- Pharmacokinetics: apparent volume of distribution of ZP4207 based on plasma concentration values (Vz), estimated during the terminal Phase (f): (Vz/f)(5 hours)
- Pharmacokinetics: apparent plasma clearance rate of ZP4207(CL) estimated during the terminal Phase (f)(5 hours)
- Pharmacokinetics: mean residence time for plasma ZP4207 (MRT)(5 hours)
- Pharmacodynamics (PD): Area under the Plasma glucose curve from time-point 0 until 300 min (AUCgluc 0-300)(5 hours)
- Pharmacodynamics: maximum observed concentration (Cmax)(5 hours)
- Pharmacodynamics: time to maximum observed concentration (tmax)TPG≥70mg/dL(5 hours)
- Pharmacodynamics: Time to plasma glucose equal or above (70 mg/dL)(5 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of HTD1801 in Healthy SubjectsPrimary Sclerosing CholangitisNCT03099603HighTide Therapeutics (Hong Kong) Limited32
已完成
1 期
Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy AdultsPulmonary TBNCT03722472Access to Advanced Health Institute (AAHI)48
已完成
2 期
A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain ManagementAnalgesia DisorderPainNCT02468128Lumosa Therapeutics Co., Ltd.221
已完成
1 期
Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023HealthyNCT05354349Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)49
已完成
1 期
A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy SubjectsHealthy VolunteersNCT05103878Bacainn Therapeutics, Inc.50